Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
ZUG, Switzerland, Feb. 18, 2016 -- Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that it will host a Key Opinion Leader breakfast focused on current advances in acute sensorineural hearing loss (ASNHL) treatment on Friday, February 26, from 8am-9:30am Eastern Time in New York City.
The meeting will feature a keynote presentation by Adrien A. Eshraghi, MD, MSc, FACS, who will discuss the pathophysiology and clinical management of acute sensorineural hearing loss, as well as several members of the Auris Medical executive management team, who will provide an overview of the Company's technology and ongoing clinical development work with AM-111 for the treatment of ASNHL.
To reserve a seat, please contact Mac MacDonald at 212-915-2567 or via e-mail at [email protected]. A live webcast of the event will be available at http://lifesci.rampard.com/20160226/reg.jsp and will be accessible through the Investors section of the Company's website at www.aurismedical.com.
Dr. Eshraghi is the Chief of Otology and Neurotology Clinics at Jackson Memorial Medical Center and Director of the University of Miami Hearing Research Laboratory. He is also a Professor of Otolaryngology and Biomedical Engineering. Dr. Eshraghi has received national and international recognition for his clinical activities, teaching, and research in the field of otolaryngology and neurotology. He has authored more than 100 scientific papers and medical book chapters related to the management of hearing loss and tinnitus. He is a fellow of the American College of Surgeons, American Academy of Otolaryngology-Head and Neck Surgery, and Otology Society. He was elected as President of the Florida Society of Otolaryngology-Head and Neck Surgery in 2015.
About Auris Medical
Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The Company is currently focusing on the development of treatments for acute inner ear tinnitus (AM-101) and for acute inner ear hearing loss (AM-111) by way of intratympanic injection with biocompatible gel formulations. In addition, Auris Medical is pursuing early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland. The shares of the parent company Auris Medical Holding AG trade on the NASDAQ Global Market under the symbol "EARS".
Contact: Matthew P. Duffy, Managing Director, LifeSci Advisors, 212-915-0685, [email protected]
HUG#1987156
